NCT01282333: Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer |
|
|
| Terminated | 1 | 44 | US | gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, veliparib, ABT-888, diagnostic laboratory biomarker analysis, pharmacological study, pharmacological studies, cisplatin, CACP, CDDP, CPDD, DDP | National Cancer Institute (NCI) | Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | 02/13 | | | |
